Ray Dorsey

@Helenlouiseford telling a packed room @MSTrust conference about the great work going on in West Yorkshire developing networked models of care for pwMS

@AgneStraukiene is asking us to rethink our approach & the language we use when talking to pwMW @MSTrust conference

@DrWBRO kicking things off at the @MSTrust conference talking us through the evolving diagnosis and classification of #MS

Headache Specialist Pharmacist Mat Garrod presenting on high cost drugs and how pharmacists can help in supporting headache pathways @TheNeuroAcademy #neuropharmacy @UKCPANeuro @MigraineTrust

@robmusic_ presenting some really interesting data around the potential impact pharmacists can have on headache management pathways @TheNeuroAcademy

Very excited to be heading into 2 days of discussion around improving headache services in the NHS @TheNeuroAcademy

Proud to have been at the House of Commons today. Looking at ways to remove barriers to MS care. Thanks to @linaruns for sharing her story. Specialist pharmacists have an important role to play in better access to MS care @ms_trust @shiftdotms @UKCPANeuro

@GilPerotin @IlNeuroDoktorMS It was a prospective randomised phase 3 trial In about 200 pts

@RayDorsey7 @IlNeuroDoktorMS is it a registry-based study?

Late breaking #ECTRIMS2025 Swedish RIDOSE study shows that RTX 500mg every 12 months is as effective as 6 monthly doses in maintaining NEDA

Late breaking #ECTRIMS2025 Combination of metformin and clemastine shows a positive effect on remyelination but not clinically significant. More studies needed

Late Breaking #ECTRIMS2025 Higher body weight doses of ocrelizumab did not reduce progression in PPMS

Late Breaking #ECTRIMS2025. Prof Giovannoni presents the first study demonstrating the benefit of a DMT (ocrelizumab) in pwMS who are EDSS > 6.5

Today is World Pharmacists Day! Celebrating the contribution of pharmacists at #ECTRIMS2025 with a record number of neuropharmacists in attendance @UKCPANeuro @UKNeuroPharmacy

Great talks in the session on managing risks of HET #ECTRIMS2025. Lots of work going on looking at alternative dosing regimes of B cell therapies. Looking forward to seeing outcomes of the BLOOM study comparing standard to B cell guided dosing ….@UKCPANeuro @UKNeuroPharmacy

Getting ready for day 2 at #ECTRIMS2025. Heading your way the session on personalised treatment regimes in #MS. See you there? #neuropharmacists @UKNeuroPharmacy @UKCPANeuro

Check out our e-poster on the evolving role of the #Pharmacist in the #MS team. P1642. #ECTRIMS2025 @ImperialNHS @UKCPANeuro @UKNeuroPharmacy

Here we go! #ECTRIMS2025 has kicked off in Barcelona. Very excited that we have at least 14 neuropharmacists attending from the UK this year! Highlighting the growing recognition of the contribution #pharmacists can make to #MS care @UKCPANeuro @UKNeuroPharmacy

@jamesavarley2 @drruthdobson @joelamathews

Some thoughts on the natalizumab biosimilar roll out. Good to reflect on what could be done differently as we move into an era of further biosimilars & generics in the MS space pn.bmj.com/content/practn…

We've just completed our 3rd #Neuropharmacy MasterClass, where delegates presented the outcomes of their workplace projects. Inspiring to see such dedication to improving services and patient care in local settings! Read more: eu1.hubs.ly/H0mnGSs0 @UKNeuroPharmacy